Speakers:

• Wendy L. Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP

Family care clinicians are the first line of defense for patients suffering from IBS, a common disorder that causes substantial reduction in health-related quality of life. The diagnosis of IBS, whether it is IBS-D, IBS-M, or IBS-C, is generally made clinically, which is impacted by recent changes in the Rome criteria. Now recognized as both a brain-gut and a gut-brain disorder, the treatment of patients with IBS has evolved significantly in the past year. Understanding the patient burden of disease, particularly symptoms that are most troublesome, is helpful in individualizing therapy. The 2018 American College of Gastroenterology IBS guidelines lend clarity to treatments found effective, including soluble fiber and several medications, while finding little evidence to support the use of therapies such as a gluten-free diet, prebiotics/probiotics/synbiotics, and antispasmodics.

Presentation presented by the Primary Care Education Consortium (PCEC). You will receive a certificate of participation for this activity. ANCC accepts AAFP Prescribed credit. and AMA PRA Category 1 Credits. 

Grant funded by Salix Pharmaceuticals, Inc.

Speakers:

• Wendy L. Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP

Palliative medicine is a relatively new specialty. It is important that advance care planning take place before a patient faces s serious illness or medical emergency. Primary care is the best place for these conversations, due to the relationship of a patient and their primary care provider. This section will explained advance care planning and how to have the sometimes difficult conversation.

Speakers:

• Brett Snodgrass, FNP-C, CPE, FACPP, FAANP

This session is provided by a commercial interest. Contact Hours will not be awarded.

The management of patients with T2DM has undergone a seismic shift from a glucose- centric to a patient-centric focus with a primary goal of reducing cardiovascular risk. The shift to focus on cardiovascular risk stems not only from the fact that microvascular and macrovascular complications continue to be common in persons with type 2 diabetes mellitus, but also from evolving evidence clearly demonstrating cardiovascular risk reduction with some antidiabetic medications. To reduce the burden of disease and improve the journey of persons with type 2 diabetes, however, requires understanding the evidence base for these benefits and differences among the antidiabetic medications, and how treatment can be individualized to address the unmet needs of each patient.

Presentation presented by the Primary Care Education Consortium (PCEC). You will receive a certificate of participation for this activity. ANCC accepts AAFP Prescribed credit. and AMA PRA Category 1 Credits.

Grant funded by Lilly.

Speakers:

• Wendy L. Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP

Low back pain is a common complaint in primary care. It is important to recognize red flags associated with low back pain, as well as evidenced based guidelines for appropriate management in primary care.

Speakers:

• Brett Snodgrass, FNP-C, CPE, FACPP, FAANP

In conjunction with the National Psoriasis Foundation this Psoriasis Recognition Program is designed to help enhance your skills in caring for those with psoriasis. After completing this program, attendees will be formally recognized as up-to-date in the latest psoriasis education.

This activity is supported by educational grants from Bristol-Myers Squibb and Janssen.

The National Psoriasis Foundation designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits^TM

Click to Register for this Program

The pharmacologic treatment of diabetic kidney disease (DKD) has typically involved treatment of associated risk factors such as blood glucose, blood pressure, and the use of medications that act on the renin-angiotensin-aldosterone system. Recently, a variety of glucose-lowering medications have been investigated to assess their potential for improved renal outcomes in patients with type 2 diabetes mellitus and with/without established DKD. Several of these medications have been shown to improve renal outcomes in patients with type 2 diabetes mellitus. This presentation seeks to provide insight into the results of these clinical trials and how the selected medications can be used to individualize therapy as recommended in updated guidelines issued by the American Diabetes Association and the American Association of Clinical Endocrinologists/ American College of Endocrinology.

*Presentation presented by the Primary Care Education Consortium (PCEC). You will receive a separate certificate of participation for this activity. ANCC accepts AAFP Prescribed credit and AMA PRA Category 1 Credits. Sponsored by PCEC and PCMG. Supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc

Speakers:

• Christine Kessler, MN, CNS, ANP-C, BC-ADM, CDTC, FAANP

This session will review the natural history of HPV, current screening guidelines for cervical cancer prevention and appropriate uses of HPV testing. There will be a discussion of HPV testing in the triage of the borderline abnormal Pap test, co-testing with Pap and HPV and an introduction to HPV primary stand-alone testing. There will be an overview of the role of HPV in anal cancer, screening with anal cytology and high resolution anoscopy as well as a look at the role of HPV in oropharyngeal cancer. There will also be a look at the next generation of risk-based management which is coming in the near future.

Speakers:

• Nancy R. Berman, MSN, ANP-BC, NCMP, FAANP

At the conclusion of this session attendees will be able to identify actinic keratosis and squamous cell cancer and determine an appropriate treatment plan, identify basal cell cancer and determine an appropriate treatment plan and identify dysplastic nevi and malignant melanoma and determine an appropriate treatment plan.

Speakers:

• Kathleen Haycraft, DNP, FNP/PNP-BC, DCNP, FAANP

2017 AHA Guidelines have tweaked the treatment of hypertension once again. What are the latest guidelines? How can you put them to work for your patients?

Speakers:

• Brett Snodgrass, FNP-C, CPE, FACPP, FAANP

This session is provided by a commercial interest. Contact Hours will not be awarded.

This session will present an overview of normal vulvar and vaginal anatomy, when and where to biopsy, and the clinical appearance and management of HPV disease including condyloma and low and high grade neoplastic disease. The session will then review common vulvar and vaginal benign disease presentations and management including lichen sclerosus, lichen simplex chronicus, lichen planus, psoriasis, and atopic dermatitis. A gallery of clinical photos will be presented along with recommendations for treatment.

Speakers:

• Nancy R. Berman, MSN, ANP-BC, NCMP, FAANP

This session will allow participants to be able to identify: Acne, Atopic Dermatitis, Warts, Tinea, Pruritis (and associated lesions) as well as treatment plans. This session will also engage learners in high level assessment and associated treatment for acne, atopic dermatitis, warts, tinea and pruritis.

Speakers:

• Kathleen Haycraft, DNP, FNP/PNP-BC, DCNP, FAANP

The emergence of genomics and precision medicine is sure to bring about seismic changes in healthcare delivery. Using case studies, this intriguing session will critically examine the expanding field of genomic medicine (including pharmacogenomics and use of biomarkers) and demonstrate how it’s integration into clinical practice may help to more precisely evaluate, diagnose, manage and prevent selected acute and chronic medical conditions.

Speakers:

• Christine Kessler, MN, CNS, ANP-C, BC-ADM, CDTC, FAANP

Using case studies, this session will provide endocrinology expert tips on how to detect, diagnose and treat the second most common endocrine disorder…thyroid disease. The focus will be on how to manipulate various thyroid hormone replacement drugs, as well as antithyroid medications in clinical and urgent situations.

Speakers:

• Christine Kessler, MN, CNS, ANP-C, BC-ADM, CDTC, FAANP

This session is provided by a commercial interest. Contact Hours will not be awarded.

COPD is a common preventable and treatable disease which is characterized by persistent airflow limitation. COPD is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases (90% of cases is due to smoking). Exacerbations and comorbidities contribute to the overall severity in individual patients. COPD management is driven by the yearly update of the GOLD Executive Summary (Global Initiative for Chronic Obstructive Lung Disease). Evidence based goal directed therapy is paramount in COPD management to slow the progression of COPD and improve patient quality of life.

Speakers:

• Jason Cross, PharmD, BCPS, BCACP

Heart failure is when the heart is unable to pump sufficiently to maintain blood flow to meet the body needs. Incidence and prevalence of heart failure will continue to rise over the next several decades due to the baby boomers and medical advancements of surviving acute coronary syndrome. Pharmacotherapy management of heart failure heavily involves evidence based goal directed therapy, which helps lower 5 year mortality rate.

Speakers:

• Jason Cross, PharmD, BCPS, BCACP

By completing this session, participants will be able to apply new evidence into practice regarding the use of diagnostic testing, treatment and chemoprophylaxis for people with, or at risk for, influenza. Also, Incorporate the use of antiviral agents into practice based on their ability to reduce transmission, as well as treat people with influenza who are at normal or high risk for complications.

Content Developed by: John J. Russell, MD, Clinical Professor of Family and Community Medicine, Thomas Jefferson University Sidney Kimmel School of Medicine, Philadelphia, PA; Chair, Department of Family Medicine and Program Director, Family Medicine Residency, Abington – Jefferson Health, Abington, PA

This activity is supported by an educational grant from Genentech, Inc.
This continuing nurse education activity is provided by Vindico Medical Education.

Speakers:

• John J. Russell, MD

Although morbidity and mortality for infectious diseases during the last century has decreased, these diseases still cause a huge impact on the population in the US and in the world. In recent years some of the mortality rates from infectious diseases have actually risen for diseases such as HIV/AIDS, West Nile Virus and clostridium difficile. Worldwide the most infectious disease deaths each year are caused by three diseases: tuberculosis, malaria, and HIV/AIDS. These diseases cause over 300 million illnesses and more than 5 million deaths annually. Pneumonia and influenza account for 40% of infectious disease mortality in the U.S. Therefore it is critical to understand these diseases and those that are new and emerging.

Speakers:

• Lynn Chilton, DSN, FNP-BC, GNP-BC

Beer’s Criteria is a guideline that was developed by a panel of interdisciplinary geriatric and pharmacotherapy experts to help healthcare professionals to determine the safety of medications for older adults. The purpose of the project was to create a comprehensive, systematic review and grading of the evidence on drug-related problems and adverse drug reactions in older adults. The medications on the Beer’s list include those that have risks that outweigh benefits for individuals over the age of 65.

Speakers:

• Lynn Chilton, DSN, FNP-BC, GNP-BC

This session will cover neurotransmitters that are targeted for treating depression and anxiety. Learn to recognize symptoms and severity of depression and anxiety disorders as listed in DSM IV and their influence on ADL. Also, get a better understanding of medication side effects, adverse events and the barriers for adherence for patients to achieve remission of their symptoms.

Speakers:

• Nancy Nadolski, MSN, M.Ed, FNP-C

Sleep disorders affect many people. This session will better prepare the learner by helping them identify healthy and normal sleep architecture across the lifespan along with the chemical neurotransmitters involved in sleep stagings. Session will review symptoms and neurotransmitters involved with insomnia, obstructive sleep apnea, restless leg syndrome, shift work sleep disorder and night terrors. Lastly, you will leave this session with a better understanding of medication interventions for all insomnia and sleep diagnosis.

Speakers:

• Nancy Nadolski, MSN, M.Ed, FNP-C